ArticleFrontiers in public health2026
A comprehensive diagnostic model for tuberculous PE: integration of clinical and immunological biomarkers.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculous pleurisy represents a prevalent form of extrapulmonary tuberculosis and constitutes a significant diagnostic challenge in clinical practice, particularly in endemic regions where it accounts for approximately 20-30% of all PEs. The nonspecific clinical presentation and the limitations of conventional diagnostic methods-including the low sensitivity and prolonged turnaround time of pleural fluid culture-often result in delayed diagnosis and treatment, potentially compromising patient outcomes. Objective: To develop and validate a comprehensive, evidence-based predictive model that integrates readily available clinical and immunological biomarkers to enhance the early and accurate diagnosis of tuberculous pleurisy, thereby supporting timely clinical decision-making and optimized patient management. Methods: We conducted a retrospective cohort study of 523 consecutive patients presenting with PE at a tertiary care center between 2010 and 2021, including 375 patients with confirmed tuberculous pleurisy and 148 with non-tuberculous effusions. Demographics, biochemical markers (adenosine deaminase, lactate dehydrogenase, C-reactive protein, D-dimer), immunological parameters (T-SPOT.TB, T-cell subsets), and clinical indicators were systematically evaluated. Statistical analyses encompassed descriptive and comparative tests, multivariate logistic regression, and receiver operating characteristic curve analysis. Missing data were addressed using median imputation (Rivalta test, 4.4%) and case-wise deletion (T-cell subsets, 14.9%). Results: Five independent predictors were significantly associated with tuberculous pleurisy: younger age, elevated adenosine deaminase, lower C-reactive protein, positive Rivalta test, and positive T-SPOT.TB result. The multivariate logistic regression model demonstrated excellent discriminative performance (pseudo Conclusion: This study presents a robust and clinically applicable diagnostic model that effectively distinguishes tuberculous pleurisy from non-tuberculous PEs by integrating multiple routinely available biomarkers. The model offers a practical, cost-effective tool for early diagnosis, with the potential to improve therapeutic timeliness and patient outcomes across varied healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.